Glimybite Trio 1mg/500mg/0.2mg Tablet SR
Marketer
Redosine Pharmaceutical Pvt Ltd
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview Glimybite Trio 1mg/500mg/0.2mg Tablet SR
TriadGlyc 1mg/500mg/0.2mg Extended-Release Tablets are classified as antidiabetic medications. This combination therapy is indicated for adult patients with type 2 diabetes mellitus to manage blood glucose levels. TriadGlyc should be administered with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial, even with well-controlled blood sugar, as abrupt cessation can elevate glucose levels, increasing the risk of kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan incorporating diet, exercise, and weight management as directed by your doctor. Lifestyle modifications are integral to diabetes control. Hypoglycemia (low blood sugar) is a common adverse effect, characterized by sweating, dizziness, headache, and tremors. Recognize these symptoms and carry a fast-acting glucose source (e.g., sugary foods, fruit juice). Alcohol consumption should be limited due to its potential to exacerbate hypoglycemia. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of heart disease should inform their physician before commencing treatment. Consult your doctor before using this medication if you are pregnant or breastfeeding. Regular blood glucose monitoring is essential, and your doctor may order blood tests to assess blood cell counts and liver function.
Uses of Glimybite Trio 1mg/500mg/0.2mg Tablet SR
Managing type 2 diabetes
Major Benefits of Glimybite Trio 1mg/500mg/0.2mg Tablet SR:
Administer this medication precisely as prescribed by your physician, adhering to the recommended dosage and treatment schedule. Ingest the entire tablet without chewing, crushing, or fracturing. Consume Glimybite Trio 1mg/500mg/0.2mg Extended-Release Tablets on an empty stomach.
Common Side effects of Glimybite Trio 1mg/500mg/0.2mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Glimybite Trio 1mg/500mg/0.2mg Tablet SR:
Follow your doctor's instructions precisely regarding the dosage and treatment length for Glimybite Trio 1mg/500mg/0.2mg Tablet SR. Ingest the tablet whole; do not chew, crush, or divide it. Administer this medication on an empty stomach.
How Glimybite Trio 1mg/500mg/0.2mg Tablet SR works:
Extended-release Glimybite Trio tablets (1mg/500mg/0.2mg) contain a triple combination of antidiabetic agents.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glimybite Trio 1mg/500mg/0.2mg SR tablets with alcohol is not advised due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
The use of Glimybite Trio 1mg/500mg/0.2mg SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against potential hazards before prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Glimybite Trio 1mg/500mg/0.2mg tablet is likely unsafe for breastfeeding mothers. Available human data indicate potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving may be impaired by excessively low or high blood glucose levels. Refrain from driving if such symptoms arise.
KidneyUNSAFE
The use of Glimybite Trio 1mg/500mg/0.2mg SR tablets poses a likely risk for individuals with kidney impairment and should be omitted. Patients should seek medical advice before using this medication. Specifically, its application is contraindicated in those with severe kidney disease.
LiverCAUTION
Patients with liver impairment should use Glimybite Trio 1mg/500mg/0.2mg Tablet SR cautiously, potentially requiring dosage modification. A physician's consultation is advised. In those with mild to moderate hepatic dysfunction, initiation should be at a reduced dose; however, its use is contraindicated in patients with severe liver disease.
What if you forget to take Glimybite Trio 1mg/500mg/0.2mg Tablet SR :
Should you forget a Glimybite Trio 1mg/500mg/0.2mg SR Tablet dose, administer it promptly. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glimybite Trio 1mg/500mg/0.2mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Diabetes medication |
3,018 People bought this recently